On May 31, 2024, Virogen Biotechnology Inc., a wholly owned U.S. subsidiary of Virogen Biotechnology, announced a strategic partnership agreement with Moffitt Cancer Center. The two parties will aim at cutting-edge technological innovation and unmet clinical needs, collaborate and complement each other in clinical research and innovative therapies, jointly promote the research and development process of VG712, and jointly develop the clinical application of VG712 in the treatment of chimeric antigen receptor T cells (CAR-T) and tumor infiltrating lymphocyte therapy (TIL). In order to meet the urgent needs of tumor patients in the field of immunotherapy, to provide better treatment options

.

Previously, VG712, the company's core program, had demonstrated a favorable safety profile and significant efficacy in a Phase I clinical trial for the treatment of cutaneous T-cell lymphoma (CTCL). At present, Wejin Biology is also actively preparing for Phase II clinical trials of CTCL in the United States and phase I trials as an immune tolerance inducer for kidney transplantation.

Weijin Biology has accumulated a wealth of expertise and research and development experience in the field of immunotoxins, and Moffitt Cancer Center has deep knowledge in the field of tumor therapy and immunology, rich clinical and non-clinical research resources and outstanding industry influence. The signing of this strategic cooperation will give full play to the resource advantages of both parties to jointly develop the next generation of breakthrough immunotherapies based on VG712, accelerate the development and commercialization of related drugs, and benefit cancer patients around the world.

Mr. Chen Su, General Manager of Weijin Biology, said, "We are honored to establish a partnership with Moffitt Cancer Center, a global leader in cancer research. "With Moffitt's outstanding clinical research capabilities, we are confident that we can accelerate the development of VG712 to address a significant unmet medical need for the benefit of patients."

Frederick L. Locke, M.D., Director of the Division of Blood and Bone Marrow Transplantation at Moffitt Cancer Center, said, "The potential of VG712 as a low-toxicity, non-chemotherapeutic drug is exciting to enable elderly patients who are unable to receive conventional chemotherapy to receive CAR-T and TIL therapy."

Patrick Hwu, M.D., President and CEO of Moffitt Cancer Center, said, "This collaboration is a great fit with our center's mission to prevent and treat cancer. We look forward to working with Vijin Biology to accelerate the development of life-saving therapies and significantly improve patient outcomes."